In vitro blood-brain barrier (BBB) models using primary rat brain microvessel endothelial cells (BMEC) are often hampered by a lack of culture purity and poor barrier properties. To address these problems, the translation inhibitor puromycin was used to purify rat BMEC cultures. BMEC purities of 99.8% were routinely attained using puromycin treatment, and this technique proved to be far superior to other purification methods of similar difficulty. In contrast to cultures without puromycin treatment, purity of puromycin-treated cultures was unaffected by initial seeding density. Next, rat BMEC monolayer transendothelial electrical resistance (TEER) was increased by glucocorticoid treatment with either corticosterone (CORT) or hydrocortisone (HC), and a corresponding decrease in monolayer permeability to small molecules was observed. Importantly, cultures treated with both puromycin and glucocorticoid attained significantly higher TEER values (CORT 168 ± 13 W · cm 2 ; HC 218 ± 66 W · cm 2 ) than those treated by the glucocorticoid alone (CORT 57 ± 5 W · cm 2 ;HC 70 ± 2 W · cm 2 ). Glucocorticoid induction resulted in BMEC morphological changes that accompanied the increases in TEER, and BMEC tight junctions exhibited improved integrity as visualized by the localization of tight junction proteins zonula occluden-1, occludin and claudin-5. The combined use of puromycin and glucocorticoid therefore provides an in vitro system that is well suited for molecular level BBB investigations. The cerebral microvasculature separates the brain interior from the bloodstream and has been termed the blood-brain barrier (BBB) as a result of its impermeable properties. The BBB assists in maintaining brain homeostasis and protects the brain against harmful blood-borne substances. A single layer of brain microvascular endothelial cells (BMEC) is responsible for the limited solute transfer between blood and brain, and these specialized endothelial cells (EC) display distinctive attributes when compared with peripheral endothelium. Low BMEC permeability results from continuous tight junctions between adjoining ECs (Reese and Karnovsky 1967), low levels of pinocytosis and a general lack of fenestrae (Brightman and Reese 1969;Joo 1971). Because of the impermeable phenotype, the BBB plays major roles in disease pathology and hinders drug delivery efforts. Because of the inherent difficulties in performing molecular level studies of disease pathology in vivo, and the fact that prediction of BBB drug permeability prior to animal studies would be highly advantageous, a representative in vitro model would be of high utility. Unfortunately, when

Glutamate transporters are thought to be assembled as trimers of identical subunits that line a central hole, possibly the permeation pathway for anions. Here, we have tested the effect of multimerization on transporter function. To do so, we coexpressed EAAC1 WT with the mutant transporter EAAC1 R446Q , which transports glutamine, but not glutamate. Application of 50 μM glutamate or 50 μM glutamine to cells coexpressing similar numbers of both transporters resulted in anion currents of 165 pA and 130 pA, respectively. Application of both substrates at the same time generated an anion current of 297 pA, demonstrating that the currents catalyzed by the wild-type and mutant transporter subunits are purely additive. This result is unexpected for anion permeation through a central pore, but could be explained by anion permeation through independently-functioning subunits. To further test the subunit independence, we coexpressed EAAC1 WT and EAAC1 H295K , a transporter with a 90-fold reduced glutamate affinity as compared to EAAC1 WT , and determined the glutamate concentration dependence of currents of the mixed transporter population. The data were consistent with two independent populations of transporters with apparent glutamate affinities similar to those of EAAC1 H295K and EAAC1 WT , respectively. Finally, we coexpressed EAAC1 WT with the pH-independent mutant transporter EAAC1 E373Q , showing two independent populations of transporters, one being pH dependent, the other being pH-independent. In conclusion, we propose that EAAC1 assembles as trimers of identical subunits, but that the individual subunits in the trimer function independently of each other.Plasma membrane glutamate transporters actively remove glutamate from the synaptic cleft after excitatory neurotransmission is complete. Uptake into the cells surrounding the synapse against a glutamate concentration gradient is achieved by these transporters by coupling transmembrane glutamate movement to the cotransport of three sodium ions and one proton, and the countertransport of one potassium ion (1,2). In addition to the movement of ions across the membrane being directly coupled to glutamate transport, glutamate transporters also catalyze uncoupled transmembrane flux of anions (3). This anion conductance is thought to be an integral property of the transporters and is not mediated by indirect coupling of transport to a secondary anion channel (3-5).Address correspondence to: Christof Grewer, PhD, Department of Physiology and Biophysics, University of Miami School of Medicine, 1600 NW 10th Avenue, Miami, FL 33136; Phone: (305) 243-1021; Fax: (305) The mammalian glutamate transporters belong to a large family of membrane transport proteins that comprise also neutral amino acid transporters, such as the alanine serine cysteine transporters (ASCTs (6,7)), and dicarboxylate transporters (8,9). A large number of biochemical data from both mammalian (10,11) and bacterial glutamate transporters (12,13), as well as recent crystallographic evidence f...

No abstract